Jade Biosciences to Participate in Upcoming Conferences
Rhea-AI Summary
Jade Biosciences (Nasdaq: JBIO), a clinical-stage biotech focused on autoimmune diseases, will participate in several September 2026 investor and healthcare conferences, including fireside chats at Wells Fargo (Sept 8, 3:45 p.m. ET), Citi (Sept 9, 9:20 a.m. ET), H.C. Wainwright (Sept 15, 1:00 p.m. ET) and the Stifel Virtual Immunology and Inflammation Forum (Sept 23, 10:30 a.m. ET).
Jade management will also hold one-on-one investor meetings, and live webcasts of the Wells Fargo, Citi and H.C. Wainwright sessions will be available on the company’s website, with replays accessible for 90 days.
Positive
- None.
Negative
- None.
News Market Reaction – JBIO
In the Sep 1 session, JBIO declined 1.59%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 10 | Earnings report | Positive | -1.1% | Q2 results and Phase 1 pipeline update; positive data accompanied financial losses and cash resources. |
| Jun 26 | Board appointment | Positive | +0.9% | Board appointment of Mark Eisner, adding clinical development and immunology experience. |
| Jun 5 | Public offering | Negative | -11.6% | Closed 11.5 million-share offering at $15.00, generating $172.5 million gross proceeds. |
| Jun 3 | Public offering | Negative | +0.8% | Priced 10 million shares at $15.00 for expected $150 million gross proceeds. |
| Jun 3 | Public offering | Negative | +0.8% | Proposed underwritten common-stock offering to fund trials, manufacturing, research, and corporate purposes. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Historical reactions diverged: earnings news preceded a 1.05% decline, while offering-related reactions ranged from a 11.57% decline to 0.85% gains.
Key Terms
immunoglobulin a nephropathy medical
afucosylated medical
monoclonal antibody medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO and VANCOUVER, British Columbia, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced its participation in the following upcoming conferences:
- Wells Fargo 21st Annual Healthcare Conference
Fireside Chat: Tuesday, September 8 at 3:45 p.m. ET - Citi 2026 Biopharma Back to School Summit
Fireside Chat: Wednesday, September 9 at 9:20 a.m. ET - H.C. Wainwright 28th Annual Global Investment Conference
Fireside Chat: Tuesday, September 15 at 1:00 p.m. ET - Stifel Virtual Immunology and Inflammation Forum
Fireside Chat: Wednesday, September 23 at 10:30 a.m. ET
Members of the Jade management team will host one-on-one investor meetings during the conferences.
A live webcast of the Wells Fargo, Citi and H.C. Wainwright fireside chats will be available on the Events & Presentations page of the Jade Biosciences website, with an archived replay accessible for 90 days following the event.
About Jade Biosciences, Inc.
Jade Biosciences is a clinical-stage biotechnology company focused on developing best-in-class therapies that address critical unmet needs in autoimmune diseases. Jade’s lead candidate, JADE101, targets the cytokine APRIL, and is currently being evaluated for the treatment of immunoglobulin A nephropathy. Jade’s pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, as well as JADE301, an anti-IFN-β monoclonal antibody. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. For more information, visit JadeBiosciences.com and follow the Company on LinkedIn.
Forward-Looking Statements
Certain statements in this communication, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the “safe harbor” provisions under the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements relating to Jade’s expectations, hopes, beliefs, intentions or strategies regarding the future of its pipeline and business including, without limitation, the potential therapeutic uses of Jade’s product candidates and their best-in-class potential. The words “opportunity,” “potential,” “milestones,” “pipeline,” “can,” “goal,” “strategy,” “target,” “anticipate,” “achieve,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “plan,” “possible,” “project,” “should,” “will,” “would” and similar expressions (including the negatives of these terms or variations of them) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Jade will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Jade’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: ongoing and any future clinical trials may be delayed or may not demonstrate desirable efficacy or predicted performance; adverse events and safety signals may occur; Jade may experience unanticipated costs, difficulties or delays in the product development process; Jade’s product candidates may be delayed to a point where they are not commercially viable; clinical trial start up, enrollment or regulatory challenges may occur; and the other risks, uncertainties and factors more fully described in Jade’s most recent filings with the Securities and Exchange Commission (including the Quarterly Report on Form 10-Q for the quarter ended June 30, 2026). Should one or more of these risks or uncertainties materialize, or should any of Jade’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. You should not place undue reliance on forward-looking statements in this communication, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Jade does not undertake or accept any duty to release publicly any updates or revisions to any forward-looking statements, except as required by law. This communication does not purport to summarize all of the conditions, risks and other attributes of an investment in Jade.
Jade Biosciences Contact
Priyanka Shah
Media@JadeBiosciences.com
IR@JadeBiosciences.com
908-447-6134
